PUBH 3100 Week 3 Mechanism Explainer Example

Seven Steps From a Healthy Artery to a Heart Attack, Each Labeled by the Study Behind It: A Mechanism Explainer on Atherosclerosis Drawing on Autopsy Series, Imaging Cohorts, Genetic Evidence and Randomized Trials

Student Name

Walden University

PUBH 3100: Human Disease and Prevention

Instructor Name

Month Day, Year

Seven Steps From a Healthy Artery to a Heart Attack, Each Labeled by the Study Behind It: A Mechanism Explainer on Atherosclerosis Drawing on Autopsy Series, Imaging Cohorts, Genetic Evidence and Randomized Trials

Why Label the Evidence

Atherosclerosis, the buildup of fatty, inflamed plaque in artery walls, underlies most heart attacks and many strokes. Explanations of it often present a smooth story in which each step follows the last. The evidence behind those steps is uneven. Some come from looking at arteries after death, some from imaging living people, some from genetics and some from trials that changed one factor and watched what happened. This explainer lays out seven steps in plain words and labels each by the kind of study that supports it, so a reader knows which links are firm and which are inferred.

Step 1: Damage and Change in the Artery Lining

The inner lining of an artery, the endothelium, normally keeps blood flowing smoothly and resists sticking. High blood pressure, smoking, high blood sugar and turbulent flow at branch points change the lining so that it lets particles in more easily and attracts white blood cells. Evidence: mainly laboratory and animal studies, supported by human studies of lining function. Libby et al. (2019) summarize this step as the starting point of plaque formation.

Step 2: Cholesterol-Carrying Particles Enter the Wall

Low-density lipoprotein (LDL) particles, which carry cholesterol in the blood, pass into the artery wall and become trapped and chemically modified. Evidence: strong and from several sources. Genetic studies show that people born with lifelong lower LDL have fewer heart attacks, and randomized trials of LDL-lowering drugs reduce events in proportion to how much LDL falls. A consensus review of genetic, observational and trial evidence concluded that LDL is a cause of atherosclerotic cardiovascular disease, not just a marker (Ference et al., 2017).

Step 3: White Blood Cells Arrive and Fill With Fat

Monocytes, a type of white blood cell, enter the wall, become macrophages and swallow the modified LDL, turning into fat-filled "foam cells." Clusters of foam cells form fatty streaks. Evidence: microscope studies of human arteries and animal models.

Step 4: Fatty Streaks Appear Early in Life

Fatty streaks are not a disease of old age. An autopsy study of young people who died of accidents, homicide or suicide found intimal lesions in the aortas of all subjects aged 15 to 19 and in more than half of their right coronary arteries, with lesions increasing in extent through ages 30 to 34 (Strong et al., 1999). Evidence: autopsy series. These studies show what arteries look like at a moment in time; they cannot follow one person's artery as it changes.

Step 5: Plaques Grow and Harden

Over years, fatty streaks can develop into raised plaques with a core of fat and dead cells covered by a fibrous cap. Some plaques calcify. Evidence: autopsy studies and imaging of living people. In a large multiethnic cohort, people whose coronary arteries showed calcium on CT scans had much higher rates of later coronary events; those with scores between 101 and 300 had about 7.7 times the adjusted risk of those with no calcium (Detrano et al., 2008). Imaging cohorts show that visible plaque predicts events, which links this step to the next.

Step 6: Inflammation Drives Plaque Instability

Inflammation inside the plaque weakens the fibrous cap. Evidence: long held from laboratory and observational studies, and tested directly in a randomized trial. In that trial, an antibody that reduces a specific inflammatory signal lowered recurrent cardiovascular events in people who had had a heart attack, without lowering cholesterol (Ridker et al., 2017). This trial is the strongest human evidence that inflammation is a cause rather than a bystander, though it tested only one inflammatory pathway.

Step 7: Rupture, Clot and Blocked Blood Flow

When a plaque's cap tears, blood contacts the plaque's core and a clot forms. If the clot blocks a coronary artery, heart muscle is starved of oxygen: a heart attack. Evidence: autopsy studies of people who died of heart attacks and imaging during heart attacks. This step is well described, but it is not yet possible to predict which plaque will rupture in a living person.

Summary Figure in Words

Table 1

Seven Steps of Atherosclerosis and the Evidence Behind Each

Note. Prepared for this explainer from the cited sources.

Where the Evidence Is Weakest

Two gaps stand out. The first is the move from step 5 to step 7. Imaging shows which people carry more plaque, and autopsy shows which plaques ruptured, but no method yet identifies in advance the particular plaque in a living person that will tear. Prevention therefore aims at lowering risk across all plaques rather than finding the dangerous one. The second gap concerns step 1. The early changes in the artery lining are well described in animals and cell studies, but human evidence comes mostly from indirect tests of how arteries widen in response to blood flow, which are hard to standardize. Neither gap undermines the overall account, which rests most firmly on step 2, but a reader should not mistake the smoothness of the seven-step story for equal certainty at every step. Labeling each step lets a reader see where future research would add the most.

What the Labels Mean for Prevention

The firmest causal links, LDL and to a lesser degree blood pressure and smoking, are the ones prevention targets most directly. The early start of fatty streaks shown in autopsy series supports prevention that begins in youth, not middle age. Steps supported mainly by laboratory work are plausible but less certain, and the explainer avoids treating them as settled.

References

Detrano, R., Guerci, A. D., Carr, J. J., Bild, D. E., Burke, G., Folsom, A. R., Liu, K., Shea, S., Szklo, M., Bluemke, D. A., O'Leary, D. H., Tracy, R., Watson, K., Wong, N. D., & Kronmal, R. A. (2008). Coronary calcium as a predictor of coronary events in four racial or ethnic groups. The New England Journal of Medicine, 358(13), 1336-1345. https://doi.org/10.1056/NEJMoa072100

Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., Watts, G. F., Borén, J., Fazio, S., Horton, J. D., Masana, L., Nicholls, S. J., Nordestgaard, B. G., van de Sluis, B., Taskinen, M.-R., . . . Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144

Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019). Atherosclerosis. Nature Reviews Disease Primers, 5, Article 56. https://doi.org/10.1038/s41572-019-0106-z

Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., Kastelein, J. J. P., Cornel, J. H., Pais, P., Pella, D., Genest, J., Cifkova, R., Lorenzatti, A., Forster, T., Kobalava, Z., . . . Glynn, R. J. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. The New England Journal of Medicine, 377(12), 1119-1131. https://doi.org/10.1056/NEJMoa1707914

Strong, J. P., Malcom, G. T., McMahan, C. A., Tracy, R. E., Newman, W. P., III, Herderick, E. E., & Cornhill, J. F. (1999). Prevalence and extent of atherosclerosis in adolescents and young adults: Implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA, 281(8), 727-735. https://doi.org/10.1001/jama.281.8.727